^
    CANCER:

    Follicular Lymphoma





    Show legend
    Group by Gene:
    Include preclinical:

    rituximab
    rituximab-abbs
    rituximab-pvvr
    		0
    CD20 inhibitor
    Rixathon (rituximab biosimilar)
    rituximab + obinutuzumab
    rituximab / hyaluronidase
    obinutuzumab
    axicabtagene ciloleucel
    		1
    CD19-targeted CAR-T immunotherapy
    lisocabtagene maraleucel
    tisagenlecleucel-T
    2
    Alkylating agent
    cyclophosphamide
    chlorambucil
    3
    PI3Kδ inhibitor
    idelalisib
    INCB50465
    4
    EZH2 inhibitor
    tazemetostat
    CPI-169
    5
    BTK inhibitor, CD20 inhibitor
    obinutuzumab + zanubrutinib
    6
    PIK3CA inhibitor, PI3Kδ inhibitor
    copanlisib
    7
    HDAC inhibitor
    CG-781
    8
    PD1 inhibitor, BTK inhibitor
    nivolumab + ibrutinib
    9
    PI3Kδ inhibitor, CD20 inhibitor
    obinutuzumab + INCB50465
    10
    PD1 inhibitor
    nivolumab
    11
    CD20-targeted CAR-T immunotherapy
    MB-106
    12
    Bcl2 inhibitor, CD20 inhibitor
    venetoclax + obinutuzumab
    13
    Cereblon modulator, Pleiotropic pathway modifier, CD20 inhibitor
    rituximab + CC-122
    14
    CD19-targeted CAR-T immunotherapy, BTK inhibitor
    acalabrutinib + axicabtagene ciloleucel
    GVD
    R-CVP
    R-CHOP
    ViPOR
    		15
    Chemotherapy
    EPOCH-R
    R-DHAP
    R-GemOx
    DHAP
    DHAX
    G-CHOP
    16
    PD-L1 inhibitor
    PD-L1 inhibitor
    17
    PI3Kγ inhibitor, PI3Kδ inhibitor
    duvelisib
    18
    CD3 agonist, CD20 inhibitor
    epcoritamab-bysp
    mosunetuzumab-axgb
    19
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide
    lenalidomide + obinutuzumab
    20
    Ionizing radiation emitter, CD20 inhibitor
    ibritumomab tiuxetan
    rituximab + ibritumomab tiuxetan
    21
    Tubulin polymerization promoter, DNA synthesis inhibitor, DNA-directed DNAP inhibitor
    carboplatin + cytarabine
    22
    TNFα inhibitor, IL-12 inhibitor, IL-6 inhibitor
    lenalidomide
    23
    JAK1 inhibitor, JAK2 inhibitor
    ruxolitinib
    24
    Casein kinase I epsilon inhibitor, PI3Kδ inhibitor
    umbralisib
    25
    CD47 inhibitor, CD20 inhibitor
    IMM0306
    26
    EZH1 inhibitor, EZH2 inhibitor
    valemetostat
    27
    PD-L1 inhibitor, Bcl2 inhibitor, CD20 inhibitor
    venetoclax + atezolizumab + obinutuzumab
    28
    CD19 inhibitor, CD3 agonist
    A-319
    29
    TNFα inhibitor, IL-12 inhibitor, CD3 agonist, IL-6 inhibitor, CD20 inhibitor
    rituximab + lenalidomide + epcoritamab-bysp
    30
    Bcl2 inhibitor
    venetoclax
    31
    Histone acetyltransferase activator
    YF2
    No biomarker
    CD20 positive
    TMB-L
    TMB-H
    CD20 positive + TMB-L
    EZH2 mutation
    CD19 positive
    CCL19 overexpression
    CCL19 elevation
    MYC rearrangement + BCL2 rearrangement
    IL2RA-L
    HAVCR2 expression
    RGL1 overexpression
    BCL2 mutation
    GNA13 mutation
    CTSS Y132D
    GNA12 mutation
    IL2-L
    FCGR2A mutation
    TBX21 overexpression
    LDH elevation
    MYC rearrangement
    PD-L1 overexpression
    IL2RA elevation
    BCL2 F104I
    TBX21 expression
    Chr del(6q)(q15)
    CXCL11 elevation
    BCL2 elevation + IGH elevation
    KMT2D mutation
    CREBBP mutation
    MYC rearrangement + BCL6 rearrangement
    TP53 mutation
    PLCG2 mutation
    TNFAIP3 mutation
    BCL7A mutation
    ARID1B mutation